Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is an echinocandin presented as a intravenous solution for intravenous use. It treats invasive candidiasis and related fungal infections in immunocompromised patients.

GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Micafungin is an echinocandin antifungal indicated for several serious Candida infections. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradicates Candida infection of the esophagus in adults. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in transplant recipients. - Candida peritonitis and intra‑abdominal infections: used to treat intra‑abdominal Candida infections.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate feeling of sickness. - Headache: occasional mild headache. - Elevated liver enzymes: mild increase in ALT/AST. - Phlebitis at infusion site: irritation or inflammation. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury or failure. - Severe hypersensitivity reactions: anaphylaxis or Stevens‑Johnson syndrome. - Acute renal failure: sudden loss of kidney function. - Severe infusion reactions: hypotension, bronchospasm.

Prior to initiating Micafungin therapy, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: evaluate baseline hepatic enzymes and monitor during treatment. - Monitor renal function: check serum creatinine especially in patients with pre‑existing kidney disease. - Review concomitant medications: avoid drugs known to cause hepatotoxicity when possible. - Use with caution in neonates and pediatric patients: limited safety data are available. - Adjust for severe hepatic impairment: dosage may need modification. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine exposure; avoid co‑administration. - Rifampin: reduced micafungin plasma levels; avoid concurrent use.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase micafungin concentrations. - Statins (e.g., simvastatin): potential for increased statin levels; monitor for myopathy. - Warfarin: possible alteration of INR; monitor coagulation parameters. - Immunosuppressants (e.g., tacrolimus): may require dose adjustment.